Bristol Myers Squibb Reports Third Quarter Financial Results

Reports Third Quarter Revenues of $11.0 Billion



Posts Third Quarter GAAP Earnings Per Share of $0.93 and Non-GAAP EPS of $2.00; Includes Net Impact of Per Share for GAAP and Non-GAAP EPS Due to...

Related Keywords

United States , Canada , China , Athens , Attikír , Greece , Puerto Rico , Russia , Ukraine , Russian Federation , Neoadjuvant Opdivo , Bristol Myers Squibb , Giovanni Caforio , Christopher Boerner , Pomalyst Imnovid , Revlimid Pomalyst , Drug Administration , Clinical Research , European Commission , Point Therapeutics Inc , Linkedin , Securities Exchange , Bristol Myers Squibb Patient Assistance Foundation , Twitter , Mirati Therapeutics Inc , Pfizer Alliance , Youtube , International Intl , Instagram , Exchange Commission , European Commission For Opdivo , Business Development , B Drug Pricing Program , Facebook , Bristol Myers , Myers Squibb , Turning Point Therapeutics , Turning Point , New Product , Includes Puerto , Bristol Myers Squibb Pfizer Alliance , Biologics License Application , Blinded Independent Central , Priority Review , New Drug Application , Prescription Drug User Fee Act , Breakthrough Therapy Designation , Psoriasis Area , Severity Index , Cell Therapy , Targeted Protein Degradation , Mirati Therapeutics , Billion Dollar Roundtable , Accepted Accounting Principles , Nimbus Therapeutics , Securities Act , Securities Exchange Act , Drug Pricing Program , Russian Federation Ukraine , Annual Report , Quarterly Reports , Current Reports , Income Taxes , Earnings Attributable , Average Common Shares Outstanding , Common Share , In Line Products , Specified Items , Months Ended September , Diluted Earnings Attributable , Statement Regarding Forward Looking , Markets ,